Insilico Medicine announced ISM6200, a selective NR3C1 (glucocorticoid receptor) inhibitor it positions as best-in-class for multiple indications including ovarian cancer, Cushing’s syndrome, obesity linked to hypercortisolism, and glaucoma. The company’s update centers on early drug-discovery progress rather than trial readouts. NR3C1 is the primary glucocorticoid receptor and a key driver in steroid-responsive pathways, which is why inhibitors are explored across endocrine, metabolic, and oncology contexts. Insilico frames the approach as a way to selectively modulate NR3C1 activity. For biotech development teams, the release highlights continued interest in receptor-selective small molecules that can open differentiated clinical programs across distinct therapeutic categories. Investors will likely focus next on what preclinical data show about selectivity, tolerability, and pathway modulation—signals needed before any clinical positioning can be confirmed.